Evidence map›Paper›PMID 42724935›Full record

ArticleBio-protocol2026

Humanizing Antibodies and Nanobodies From Scratch With HuDiff.

Yang Nan, Hongshuai Sun, Bo Zhang, Yue Yang, Jianxin He, Qifeng Bai

Abstract read
In one paragraph

Article in Bio-protocol, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yang NanSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Hongshuai SunSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Bo ZhangSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
Yue YangKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest Minzu University, No.1 Xibeixincun, Chengguan District, Lanzhou, Gansu 730030, China.
Jianxin HeCollege of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Qifeng BaiSchool of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody (Ab) and nanobody (Nb) humanization is essential for reducing immunogenicity in therapeutic applications. HuDiff is an adaptive autoregressive diffusion approach that generates humanized antibodies and nanobodies from scratch using only complementarity-determining region sequences as input, eliminating the need for preexisting human templates. The method follows a two-stage training pipeline: pretraining on human antibody sequences to learn framework region patterns, followed by fine-tuning on target-species sequences. HuDiff-Ab processes paired heavy and light chains for conventional antibodies, while HuDiff-Nb can incorporate a specialized inpainting mode to preserve critical nanobody framework residues. This protocol provides a complete step-by-step guide for implementing HuDiff, covering data preparation, model training, and sequence generation. Key features • Requires only CDR sequences as input and does not require human template selection. • Uses a two-stage training strategy, with pretraining on human antibody sequences and fine-tuning on target-species sequences guided by humanness scores. • HuDiff-Ab humanizes paired heavy and light chains simultaneously, whereas HuDiff-Nb provides an inpainting mode to preserve key framework residues. • Generates multiple diverse humanized candidates for downstream experimental screening.

Indexed as

AntibodyAutoregressive diffusion modelDeep learningHumanizationNanobodyProtein design

Identifiers

PMID42724935
PMCPMC13561673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.